Pfizer PFE Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenues: by Product | |||||
| Abrysvo | $1.03B+36.8% | $755M-15.2% | $890M— | —— | |
| Adcetris | $908M-16.6% | $1.09B+1,845% | $56M— | $0— | |
| All other Oncology | $1.33B+10.9% | $1.2B-9.1% | $1.32B-28.4% | $1.85B+679% | |
| All other Primary Care | $2.86B-6.6% | $3.06B-2.1% | $3.13B+24.0% | $2.52B— | |
| All other Specialty Care | $1.76B+9.3% | $1.61B+19.2% | $1.35B— | —— | |
| Bosulif | $611M-5.1% | $644M-0.3% | $646M+12.3% | $575M+6.5% | |
| Braftovi/Mektovi | $717M+18.1% | $607M+27.0% | $478M+4.8% | $456M— | |
| Cibinqo | $284M+32.1% | $215M+68.0% | $128M+374% | $27M— | |
| Comirnaty | $4.37B-18.4% | $5.35B-52.3% | $11.22B-70.3% | $37.81B+2.8% | |
| Eliquis | $7.96B+8.1% | $7.37B+9.2% | $6.75B+4.1% | $6.48B+8.6% | |
| Elrexfio | $304M+130% | $132M+1,220% | $10M— | $0— | |
| Enbrel (Outside the U.S. and Canada) | $627M-9.1% | $690M-16.8% | $829M-17.3% | $1B-15.4% | |
| FSME-IMMUN/TicoVac | $319M+13.9% | $280M+4.5% | $268M+34.0% | $200M+8.1% | |
| Genotropin | $446M-5.1% | $470M-12.8% | $539M+49.7% | $360M-7.5% | |
| Ibrance | $4.12B-5.6% | $4.37B-8.1% | $4.75B-7.1% | $5.12B-5.8% | |
| Inlyta | $923M-5.6% | $978M-5.6% | $1.04B+3.3% | $1B+0.1% | |
| Lorbrena | $1.02B+39.8% | $732M+36.1% | $538M+56.4% | $344M+29.3% | |
| Nurtec ODT/Vydura | $1.42B+12.7% | $1.26B+36.1% | $929M+336% | $213M— | |
| Octagam | $418M-17.9% | $509M+108% | $245M+31.7% | $186M— | |
| Oncology Biosimilars | $1.3B+25.5% | $1.04B-26.3% | $1.41B-19.7% | $1.75B— | |
| Orgovyx | $421M— | —— | $120M— | —— | |
| Padcev | $1.94B+22.2% | $1.59B+2,896% | $53M— | $0— | |
| Pfizer CentreOne | $1.35B+18.0% | $1.15B-9.8% | $1.27B-5.3% | $1.34B-22.5% | |
| Prevnar Family | $6.49B+1.3% | $6.41B-1.4% | $6.5B+2.5% | $6.34B+20.3% | |
| Sulperazon (Outside the U.S. and Canada) | $653M+2.7% | $636M-16.0% | $757M-3.7% | $786M+15.2% | |
| Talzenna | $182M+55.6% | $117M+82.8% | $64M+33.3% | $48M— | |
| Tivdak | $148M+12.1% | $132M+3,200% | $4M— | $0— | |
| Tukysa | $463M-3.5% | $480M+2,567% | $18M— | $0— | |
| Vyndaqel family | $6.38B+17.0% | $5.45B+64.1% | $3.32B+35.7% | $2.45B+21.4% | |
| Xeljanz | $1.09B-6.9% | $1.17B-31.4% | $1.7B-5.2% | $1.8B-26.8% | |
| Xtandi | $2.19B+7.6% | $2.04B+22.9% | $1.66B+0.5% | $1.65B— | |
| Zavicefta (Outside the U.S. and Canada) | $637M+8.7% | $586M+14.7% | $511M+24.0% | $412M0.0% | |
| Zithromax | $400M-16.7% | $480M+18.2% | $406M+22.7% | $331M+19.1% | |
| Indefinite-lived intangible assets, period increase (decrease) by Product | |||||
| Padcev | -$600M— | —— | -$2.1B— | —— | |
| Revenues: by Geography | |||||
| International Developed Markets | $16.19B+0.8% | $16.06B-23.2% | $20.91B-48.4% | $40.53B— | |
| International Emerging Markets | $9.31B+4.9% | $8.88B-15.4% | $10.5B-39.4% | $17.32B— | |
| U.S. | $37.08B-4.2% | $38.69B+37.5% | $28.15B-35.0% | $43.32B+45.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
